ReleaseWire

Global Market Direct's pharmaceuticals report, "Edgemont Pharmaceuticals, LLC - Product Pipeline Review - 2013" provides data on the Edgemont Pharmaceuticals, LLC's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Markets Direct's, 'Proteinuria - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Proteinuria, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Proteinuria. Proteinuria - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Global Markets Direct's, 'Nasopharyngitis (Common Cold) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Nasopharyngitis (Common Cold), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Nasopharyngitis (Common Cold). Nasopharyngitis (Common Cold) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Global Market Direct's pharmaceuticals report, "Acucela Inc. - Product Pipeline Review - 2013" provides data on the Acucela Inc.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Market Direct's pharmaceuticals report, "Affibody AB - Product Pipeline Review - 2013" provides data on the Affibody AB's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Markets Direct's, 'Ebola and Marburg Infections - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Ebola and Marburg Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ebola and Marburg Infections. Ebola and Marburg Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Eylea (Microvascular Complications of Diabetes) - Forecast and Market Analysis to 2022

Global Markets Direct's, 'Shigella Infections (Shigellosis) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Shigella Infections (Shigellosis), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Shigella Infections (Shigellosis). Shigella Infections (Shigellosis) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Global Market Direct's pharmaceuticals report, "Lipocine Inc. - Product Pipeline Review - 2013" provides data on the Lipocine Inc.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Market Direct's pharmaceuticals report, "Galenea Corp. - Product Pipeline Review - 2013" provides data on the Galenea Corp.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Markets Direct's, 'Warts - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Warts, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Warts. Warts - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Global Market Direct's pharmaceuticals report, "Jeil Pharmaceutical Co., Ltd. - Product Pipeline Review - 2013" provides data on the Jeil Pharmaceutical Co., Ltd.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Market Direct's pharmaceuticals report, "Immunotope, Inc. - Product Pipeline Review - 2013" provides data on the Immunotope, Inc.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Market Direct's pharmaceuticals report, "Helsinn Healthcare S.A. - Product Pipeline Review - 2013" provides data on the Helsinn Healthcare S.A.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Market Direct's pharmaceuticals report, "Immunotope, Inc. - Product Pipeline Review - 2013" provides data on the Immunotope, Inc.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Market Direct's pharmaceuticals report, "Selvita S.A - Product Pipeline Review - 2013" provides data on the Selvita S.A's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Market Direct's pharmaceuticals report, "Mochida Pharmaceutical Co., Ltd. - Product Pipeline Review - 2013" provides data on the Mochida Pharmaceutical Co., Ltd.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Markets Direct's, 'Bladder Carcinoma - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Bladder Carcinoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bladder Carcinoma. Bladder Carcinoma - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Global Market Direct's pharmaceuticals report, "Cardio3 BioSciences SA - Product Pipeline Review - 2013" provides data on the Cardio3 BioSciences SA's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Markets Direct's, 'Malignant Glioma - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Malignant Glioma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Malignant Glioma. Malignant Glioma - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Global Market Direct's pharmaceuticals report, "Selecta Biosciences, Inc. - Product Pipeline Review - 2013" provides data on the Selecta Biosciences, Inc.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

"Pharmaceutical Business Confidence Report Q1 2014" is a new report by Kable that analyzes pharmaceutical industry executives' views on the global economy, expectations on customer confidence, supplier prices, key business concerns, and how executives' future investments are set to change in Q1 2014. This report also gives you access to regional analysis of industry outlook, industry and company growth prospects, future opportunities, staff hiring, and sales performance. Apart from providing access to the opinions and strategies of global pharmaceutical industry executives, it also examines their actions surrounding business priorities, threats and opportunities, and future investment areas over the next six months. Moreover, this report provides a comparative analysis of survey results with Q4 2013 wherever applicable.

Global Market Direct's pharmaceuticals report, "Faron Pharmaceuticals Oy - Product Pipeline Review - 2013" provides data on the Faron Pharmaceuticals Oy's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Markets Direct's, 'Corticosteroid-Responsive Dermatoses - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Corticosteroid-Responsive Dermatoses, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Corticosteroid-Responsive Dermatoses. Corticosteroid-Responsive Dermatoses - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Global Market Direct's pharmaceuticals report, "ContraFect Corporation - Product Pipeline Review - 2013" provides data on the ContraFect Corporation's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.